4 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Lead: new trials by email Literature Review of Lead trials Research Report on Lead
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial ablative single-dose PBI - Recurrent Breast Carcinoma, Ipsilateral Recurrence | Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 25 | 2025-01-01 | 2026-07-16 |
| Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy Prednisone, IVIg - Immune Thrombocytopenia | Phase 2 | Unknown | Peking University People's Hospital | 100 | 2023-10-19 | 2024-08-29 |
| A Study of Lerociclib in Participants With Advanced Breast Cancer Lerociclib + Letrozole or Fulvestrant - Advanced Breast Cancer | Phase 2 | Terminated | EQRx, Inc. | 100 | 2021-12-21 | 2026-05-14 |
| Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 32 | 2017-11-29 | 2026-09-17 |
| Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2 - Carcinoma, Pancreatic Ductal | Phase 1 / Phase 2 | Completed | Silence Therapeutics GmbH | 29 | 2013-03-01 | 2016-03-11 |
| Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer pre, during and pos-treatment swallowing exercises - Head Neck Cancer, Swallowing Disorders | Phase 2 | Completed | Barretos Cancer Hospital | 94 | 2012-07-01 | 2017-06-28 |
| Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis Vitamin E, Placebo - Peripheral Neuropathy | Phase 2 | Completed | Felipe Melo Cruz | 38 | 2009-08-01 | 2012-02-01 |
Adenocarcinoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Communication Disorders (1) · Deglutition Disorders (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Peripheral Nervous System Diseases (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Amsterdam UMC, location VUmc (1) · Barretos Cancer Hospital (1) · Case Comprehensive Cancer Center (1) · EQRx, Inc. (1) · Evopoint Biosciences Inc. (1) · Felipe Melo Cruz (1) · Peking University People's Hospital (1) · Silence Therapeutics GmbH (1)
Brazil (2) · United States (2) · Belgium (1) · China (1) · Georgia (1) · Germany (1) · Italy (1) · Mexico (1) · Moldova (1) · Netherlands (1)
Alexandre Jacinto, MD (1) · Auro del Giglio, phD (1) · Dirk Strumberg, Prof.Dr.med. (1) · Juliana Portas, MSC (1) · Luciano S Viana, PHD (1) · Tiffany Hodges, MD (1) · Xiaohui Zhang, Professor (1)